Bora Pharmaceuticals and Onconic Therapeutics have signed a manufacturing agreement to support the U.S. clinical development of JAQBO tablets, a potassium-competitive acid blocker being studied for gastroesophageal reflux disease. The partnership will use Bora’s newest oral solid dose facility in Maple Grove, Minnesota, to support production for Onconic’s planned U.S. Phase 3 trial.
Under the agreement, Bora will also provide quality control, stability testing, and chemistry, manufacturing and controls documentation support for the program. Bora said the collaboration reflects its role as a global pharmaceutical manufacturing partner for companies preparing for U.S. development and commercialization. Onconic said the deal is an important step in building the manufacturing and quality data package needed for JAQBO’s U.S. clinical development.
JAQBO is Onconic’s independently developed therapy for GERD, a condition affecting about 20% of the U.S. population. The company said P-CAB therapies are gaining attention because of their rapid and sustained acid suppression profile. JAQBO was approved in Korea in April 2024 as the country’s 37th domestically developed new drug and launched there in October 2024.
Onconic said JAQBO has shown strong prescription growth in Korea and that the company has continued expanding global development and commercialization partnerships across multiple markets. Bora Chairman and CEO Bobby Sheng said the right manufacturing partner can help programs move forward more quickly in highly regulated markets. Onconic said it will proceed without delay with U.S. development preparation and work to strengthen JAQBO’s global competitiveness.